Robert John Fontana1, Elizabeth Theresa Cirulli2, Jiezhun Gu2, David Kleiner3, David Ostrov4, Elizabeth Phillips5, Ryan Schutte4, Huiman Barnhart2, Naga Chalasani6, Paul Brent Watkins7, Jay H Hoofnagle8. 1. University of Michigan, Ann Arbor, MI, United States. Electronic address: rfontana@med.umich.edu. 2. Duke University, Durham, NC, United States. 3. National Cancer Institute, Bethesda, MD, United States. 4. University of Florida College of Medicine, Gainesville, FL, United States. 5. Vanderbilt University School of Medicine, Nashville, TN, United States. 6. Indiana University, Indianapolis, IN, United States. 7. University of North Carolina, Chapel Hill, NC, United States. 8. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, United States.
Abstract
BACKGROUND & AIMS: Terbinafine is an antifungal agent that has been associated with rare instances of hepatotoxicity. In this study we aimed to describe the presenting features and outcomes of patients with terbinafine hepatotoxicity and to investigate the role of human leukocyte antigen (HLA)-A*33:01. METHODS: Consecutive high causality cases of terbinafine hepatotoxicity enrolled into the Drug Induced Liver Injury Network were reviewed. DNA samples underwent high-resolution confirmatory HLA sequencing using the Ilumina MiSeq platform. RESULTS: All 15 patients with terbinafine hepatotoxicity were more than 40 years old (median = 57 years), 53% were female and the median latency to onset was 38 days (range 24 to 114 days). At the onset of drug-induced liver injury, 80% were jaundiced, median serum alanine aminotransferase was 448 U/L and alkaline phosphatase was 333 U/L. One individual required liver transplantation for acute liver failure during follow-up, and 7 of the 13 (54%) remaining individuals had ongoing liver injury at 6 months, with 4 demonstrating persistently abnormal liver biochemistries at month 24. High-resolution HLA genotyping confirmed that 10 of the 11 (91%) European ancestry participants were carriers of the HLA-A*33:01, B*14:02, C*08:02 haplotype, which has a carrier frequency of 1.6% in European Ancestry population controls. One African American patient was also an HLA-A*33:01 carrier while 2 East Asian patients were carriers of a similar HLA type: A*33:03. Molecular docking studies indicated that terbinafine may interact with HLA-A*33:01 and A*33:03. CONCLUSIONS: Patients with terbinafine hepatotoxicity most commonly present with a mixed or cholestatic liver injury profile and frequently have residual evidence of chronic cholestatic injury. A strong genetic association of HLA-A*33:01 with terbinafine drug-induced liver injury was confirmed amongst Caucasians. LAY SUMMARY: A locus in the human leukocyte antigen gene (HLA-A*33:01, B*14:02, C*08:02) was significantly overrepresented in Caucasian and African American patients with liver injury attributed to the antifungal medication, terbinafine. These data along with the molecular docking studies demonstrate that this genetic polymorphism is a plausible risk factor for developing terbinafine hepatotoxicity and could be used in the future to help doctors make a diagnosis more rapidly and confidently.
BACKGROUND & AIMS:Terbinafine is an antifungal agent that has been associated with rare instances of hepatotoxicity. In this study we aimed to describe the presenting features and outcomes of patients with terbinafinehepatotoxicity and to investigate the role of humanleukocyte antigen (HLA)-A*33:01. METHODS: Consecutive high causality cases of terbinafinehepatotoxicity enrolled into the Drug Induced Liver Injury Network were reviewed. DNA samples underwent high-resolution confirmatory HLA sequencing using the Ilumina MiSeq platform. RESULTS: All 15 patients with terbinafinehepatotoxicity were more than 40 years old (median = 57 years), 53% were female and the median latency to onset was 38 days (range 24 to 114 days). At the onset of drug-induced liver injury, 80% were jaundiced, median serum alanine aminotransferase was 448 U/L and alkaline phosphatase was 333 U/L. One individual required liver transplantation for acute liver failure during follow-up, and 7 of the 13 (54%) remaining individuals had ongoing liver injury at 6 months, with 4 demonstrating persistently abnormal liver biochemistries at month 24. High-resolution HLA genotyping confirmed that 10 of the 11 (91%) European ancestry participants were carriers of the HLA-A*33:01, B*14:02, C*08:02 haplotype, which has a carrier frequency of 1.6% in European Ancestry population controls. One African American patient was also an HLA-A*33:01 carrier while 2 East Asian patients were carriers of a similar HLA type: A*33:03. Molecular docking studies indicated that terbinafine may interact with HLA-A*33:01 and A*33:03. CONCLUSIONS:Patients with terbinafinehepatotoxicity most commonly present with a mixed or cholestatic liver injury profile and frequently have residual evidence of chronic cholestatic injury. A strong genetic association of HLA-A*33:01 with terbinafinedrug-induced liver injury was confirmed amongst Caucasians. LAY SUMMARY: A locus in the human leukocyte antigen gene (HLA-A*33:01, B*14:02, C*08:02) was significantly overrepresented in Caucasian and African American patients with liver injury attributed to the antifungal medication, terbinafine. These data along with the molecular docking studies demonstrate that this genetic polymorphism is a plausible risk factor for developing terbinafinehepatotoxicity and could be used in the future to help doctors make a diagnosis more rapidly and confidently.
Authors: M Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J Urban; Guruprasad P Aithal; Raúl J Andrade; Christopher P Day; Francisco Ruiz-Cabello; Peter T Donaldson; Camilla Stephens; Munir Pirmohamed; Manuel Romero-Gomez; Jose Maria Navarro; Robert J Fontana; Michael Miller; Max Groome; Emmanuelle Bondon-Guitton; Anita Conforti; Bruno H C Stricker; Alfonso Carvajal; Luisa Ibanez; Qun-Ying Yue; Michel Eichelbaum; Aris Floratos; Itsik Pe'er; Mark J Daly; David B Goldstein; John F Dillon; Matthew R Nelson; Paul B Watkins; Ann K Daly Journal: Gastroenterology Date: 2011-04-12 Impact factor: 22.682
Authors: Julia Pingel; Ute V Solloch; Jan A Hofmann; Vinzenz Lange; Gerhard Ehninger; Alexander H Schmidt Journal: Hum Immunol Date: 2012-11-29 Impact factor: 2.850
Authors: Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson Journal: J Comput Chem Date: 2009-12 Impact factor: 3.376
Authors: Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly Journal: Gastroenterology Date: 2016-12-30 Impact factor: 22.682
Authors: Faviel F González-Galarza; Louise Y C Takeshita; Eduardo J M Santos; Felicity Kempson; Maria Helena Thomaz Maia; Andrea Luciana Soares da Silva; André Luiz Teles e Silva; Gurpreet S Ghattaoraya; Ana Alfirevic; Andrew R Jones; Derek Middleton Journal: Nucleic Acids Res Date: 2014-11-20 Impact factor: 19.160
Authors: Jay H Hoofnagle; Herbert L Bonkovsky; Elizabeth J Phillips; Yi-Ju Li; Jawad Ahmad; Huiman Barnhart; Francisco Durazo; Robert J Fontana; Jiezhun Gu; Ikhlas Khan; David E Kleiner; Christopher Koh; Don C Rockey; Leonard B Seeff; Jose Serrano; Andrew Stolz; Hans L Tillmann; Raj Vuppalanchi; Victor J Navarro Journal: Hepatology Date: 2021-05-17 Impact factor: 17.425